Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

133.20USD
7:50pm BST
Change (% chg)

$0.57 (+0.43%)
Prev Close
$132.63
Open
$132.28
Day's High
$133.64
Day's Low
$132.22
Volume
428,866
Avg. Vol
1,801,006
52-wk High
$137.07
52-wk Low
$109.32

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $355,978.91
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.53

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.43 30.61 31.81
EPS (TTM): 5.91 -- --
ROI: 13.49 14.48 14.02
ROE: 22.63 15.57 15.34

J&J ordered to pay $417 million in trial over talc cancer risks

Johnson & Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

7:21pm BST

J&J ordered to pay $417 million in trial over talc cancer risks

Johnson & Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

7:20pm BST

UPDATE 1-J&J ordered to pay $417 mln in trial over talc cancer risks

Aug 21 Johnson & Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

7:18pm BST

J&J ordered to pay $417 mln in trial over talc cancer risks

Aug 21 Johnson & Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

6:51pm BST

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

18 Aug 2017

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

Aug 18 A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

18 Aug 2017

BRIEF-Bavarian Nordic announces price for shares to be issued to Johnson & Johnson Innovation

* Bavarian Nordic A/S says subscription price is dkk 405.1578 per share of dkk 10

09 Aug 2017

BRIEF-DePuy Synthes collaborates with Medical Enterprises Distribution to co-market ME1000

* DePuy Synthes says exclusive agreement with Medical Enterprises Distribution to co-market ME1000 surgical impactor for use in Total Hip Arthroplasty

07 Aug 2017

FDA panel votes against approval of J&J arthritis drug

The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

02 Aug 2017

UPDATE 1-U.S. FDA panel votes against approval of J&J arthritis drug

Aug 2 The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

02 Aug 2017

Earnings vs. Estimates